1. Home
  2. CVNA vs INSM Comparison

CVNA vs INSM Comparison

Compare CVNA & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carvana Co.

CVNA

Carvana Co.

HOLD

Current Price

$447.42

Market Cap

45.0B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$163.22

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVNA
INSM
Founded
2012
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.0B
41.2B
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
CVNA
INSM
Price
$447.42
$163.22
Analyst Decision
Buy
Strong Buy
Analyst Count
22
22
Target Price
$442.45
$187.30
AVG Volume (30 Days)
4.0M
3.9M
Earning Date
02-18-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.40
N/A
Revenue
$18,266,000,000.00
$447,022,000.00
Revenue This Year
$48.93
$49.51
Revenue Next Year
$27.67
$134.47
P/E Ratio
$100.80
N/A
Revenue Growth
45.55
30.34
52 Week Low
$148.25
$60.40
52 Week High
$485.33
$212.75

Technical Indicators

Market Signals
Indicator
CVNA
INSM
Relative Strength Index (RSI) 54.23 35.08
Support Level $450.76 $168.01
Resistance Level $474.50 $186.74
Average True Range (ATR) 18.05 6.42
MACD -1.16 -1.12
Stochastic Oscillator 67.72 13.93

Price Performance

Historical Comparison
CVNA
INSM

About CVNA Carvana Co.

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: